Fig. 4: IPMGs define the state of TIME across cancer types.
From: Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment
a Clustering of patients based on the ssGSEA score of the top 40 IPMGs. A total of 2836 patients across 32 cancer types were clustered into three groups. b The survival of patients receiving immunotherapy differed significantly in the three groups. c No significant survival difference was observed among patient groups receiving non-immunotherapy. d The “dN/dS” value of IPMGs in four pathways. Each boxplot represents the distribution of “dN/dS” values across all cancer types for a gene. The Y axis was log transformed. Most of the IPMGs are not positively selected in cancer. e The expression level of MALT1 was positively associated with the improved survival of immunotherapy-treated patients based on mutation-corrected expression (the result of fraction-corrected expression was showed in Supplementary Fig. 5d). f The expression level of CLEC4D was positively associated with the improved survival of immunotherapy-treated patients based on mutation-corrected expression (the result of fraction-corrected expression was shown in Supplementary Fig. 5e).
